Tazarotene

Tazarotene
Skeletal formula of tazarotene
Space-filling model of the tazarotene molecule
Clinical data
Trade namesTazorac, others
AHFS/Drugs.comMonograph
Routes of
administration		Topical
ATC code
Legal status
Legal status
  • CA: ℞-only / Schedule D[1]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding>99%
Elimination half-life19 Hours
Identifiers
  • ethyl 6-[2-(4,4-dimethyl-3,4-dihydro-2H-1-benzothiopyran-6-yl)ethynyl]pyridine-3-carboxylate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.115.380 Edit this at Wikidata
Chemical and physical data
FormulaC21H21NO2S
Molar mass351.46 g·mol−1
3D model (JSmol)
  • O=C(OCC)c1ccc(nc1)C#Cc3ccc2SCCC(c2c3)(C)C
  • InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3 checkY
  • Key:OGQICQVSFDPSEI-UHFFFAOYSA-N checkY
  (verify)

Tazarotene, sold under the brand name Tazorac, among others, is a third-generation prescription topical retinoid.[2][3] It is primarily used for the treatment of plaque psoriasis and acne.[4] Tazarotene is also used as a therapeutic for photoaged and photodamaged skin.[4] It is a member of the acetylenic class of retinoids.[4]

Tazarotene was approved for medical use in 1997[5] and is available as a generic medication.[6][7]

  1. ^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. August 3, 2022. Retrieved March 25, 2024.
  2. ^ Thielitz A, Abdel-Naser MB, Fluhr JW, Zouboulis CC, Gollnick H (December 2008). "Topical retinoids in acne--an evidence-based overview". J Dtsch Dermatol Ges. 6 (12): 1023–31. doi:10.1111/j.1610-0387.2008.06741.x. PMID 18479477.
  3. ^ American Society of Health-System Pharmacists, Inc. "Tazarotene". MedlinePlus Drug Information. U.S. National Library of Medicine. Retrieved September 16, 2017.
  4. ^ a b c "Tazarotene Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved March 11, 2021.
  5. ^ "Arazlo (tazarotene) [package insert]" (PDF). Drugs@FDA. U.S. Food and Drug Administration. Retrieved March 11, 2021.
  6. ^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). March 3, 2023. Archived from the original on June 30, 2023. Retrieved June 30, 2023.
  7. ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). June 29, 2023. Archived from the original on June 29, 2023. Retrieved June 29, 2023.